ProCook Group PLC (PROC:LSE) presented a strong H1 FY26 investor update demonstrating continued momentum against its medium-term strategy to reach 100 UK stores, £100 million in revenue, and a 10% operating margin. The company delivered record first-half revenue of £34.1 million, up 20.6% year-on-year, with robust like-for-like growth of 8.1% accelerating to double digits in Q2, driven by volume growth, market share gains, and disciplined promotional activity. Gross margin improved by 130 basis points, contributing to a 22.8% increase in gross profit and a 129% uplift in EBITDA to £2.3 million, while operating losses narrowed year-on-year despite cost pressures from wage inflation, National Insurance increases, and short-term dilution from new store openings. ProCook continued to execute its store rollout strategy, opening six stores in H1 and a further four early in H2, supported by a new premium-format store design that is delivering encouraging early trading and customer feedback, with average payback periods of around two years. E-commerce performance remained a key growth driver, with like-for-like growth of 15.7% in H1 and significant improvements in channel profitability through higher average order values and marketing efficiency. The company also reported a strong start to H2, with total revenue up 28.4% and like-for-like growth of 18.2% over the first eight weeks, reinforcing confidence in delivering full-year results in line with market expectations. Management emphasised continued cost discipline, selective investment, and scalable operating leverage as ProCook progresses toward sustainable profitability and long-term shareholder value creation.

Utilico Emerging Markets Trust PLC (UEM:LSE) delivered an investor presentation outlining its long-term performance track record, differentiated investment strategy, and continued confidence in emerging markets infrastructure as a source of sustainable income and capital growth. The trust is a closed-end investment company focused on listed, operational infrastructure and utility assets across emerging markets, targeting cash-generative businesses with validated operating performance, strong management teams, and long-duration growth drivers. Management highlighted more than 20 years of outperformance versus the MSCI Emerging Markets Index, 9.4% compound NAV growth since inception, and a consistently covered, growing quarterly dividend, supported by the fact that over 80% of portfolio holdings pay dividends. The portfolio is constructed on a benchmark-agnostic, bottom-up basis, typically holding 60–70 high-conviction investments, resulting in an active share of around 98% and a low beta profile. Key structural growth themes underpinning the strategy include social infrastructure (water, sanitation, transport), energy growth and transition, digital infrastructure (notably data centres), and global trade assets such as ports. The trust emphasised that emerging markets remain attractively valued relative to developed markets, with the portfolio trading at a meaningful discount on an EV/EBITDA basis versus the MSCI EM index, while the trust itself trades at a double-digit discount to NAV with a circa 3.5% yield. Management reiterated confidence in the resilience of the portfolio through economic cycles, disciplined capital allocation, selective share buybacks, and the long-term opportunity for discount narrowing as emerging markets regain investor favour.

IXICO PLC’s final results investor update highlights a strong year of company performance, accelerating revenue growth, and expanding market opportunity within the CNS imaging and analytics CRO sector. The group reported 13% revenue growth to £6.5m, improving gross margins approaching 50%, and a reduced EBITDA loss, supported by disciplined cost management, enhanced operational efficiency, and the scalability of its AI-enabled neuroimaging platform. IXICO also reported a sharp increase in contracted revenue, with its order book rising to £17.7m—up 27% since year-end—providing 84% visibility on FY2026 revenue guidance of £7.5m and underpinning a clear path toward margin expansion and operational break-even.

Narf Industries PLC (NARF:LSE) provided a comprehensive investor update highlighting strong financial momentum, accelerating contract wins, and strategic progress across its AI-driven cybersecurity platform. The company reported a 74% increase in revenue to approximately £2 million for the six months to 30 September, a materially improved loss position, and a strengthened cash balance, supported by non-dilutive government research and development (GR&D) funding and a £3 million director loan facility. Post-period, North secured a further £3.6 million GR&D contract, taking total calendar-year awards above £10 million and reinforcing the GR&D division as a core driver of revenue, cash flow, and proprietary IP. Management emphasised the effectiveness of its business model, using targeted government-funded R&D to build compounding technical capabilities that transition into higher-margin mission and services contracts. A key focus is Ranger AI, the company’s flagship cybersecurity product, developed with approximately £4 million of government funding and now mission-ready, with initial customer traction and contract discussions expected to progress in Q1 2026. Ranger AI sits on a broader agentic AI platform that codifies deep software security expertise into scalable AI agents, addressing critical risks in open-source software supply chains, reducing enterprise and government cybersecurity workloads, and enabling faster vulnerability detection and remediation. With awardable status on the US Department of Defense Platform One marketplace, a growing pipeline of defence and enterprise opportunities, and a SaaS-led revenue model complemented by integration and mission services, North Industries outlined a clear growth strategy focused on revenue growth, margin expansion, and long-term shareholder value creation.

NextEnergy Solar Fund Limited (NESF:LSE) provided a detailed investor update outlining resilient company performance, stable financial results, and a disciplined growth strategy amid challenging listed infrastructure market conditions. The fund reported cash income of £48.3 million for the period to 30 September 2025, supporting a fully cash-covered dividend target of 8.43p per share, with forecast dividend cover of 1.1–1.3x and in-period cover of 1.7x. NAV per share stood at 88.8p, with movements largely driven by externally sourced long-term power price assumptions rather than operational performance. The 101-asset portfolio, totalling c.939MW of capacity, delivered strong generation outperformance, benefiting from 13% higher-than-forecast irradiation, while active asset management, inverter repowering and cost reductions continued to enhance margins and cash flow resilience. Gearing remained disciplined at 49.2%, with ongoing debt amortisation aligned to subsidy life and further deleveraging planned through a capital recycling programme. Around 50% of revenues are underpinned by long-term government-backed subsidies, and 93% of current-year revenues are hedged, providing high visibility over cash flows and EBITDA. The board is undertaking a full strategic review, with all options under consideration to maximise total shareholder return and narrow the share price discount to NAV, with conclusions expected in early 2026. Management highlighted long-term growth opportunities aligned with the UK’s Clean Power 2030 agenda, including solar and battery storage, while maintaining a focus on capital discipline, NAV growth, and sustainable income for investors.

Star Energy Group PLC’s latest investor update highlights resilient company performance, disciplined capital management, and a clear growth strategy following recent UK budget announcements that reduced sector uncertainty. Management emphasised the group’s strong cash flow, stable production levels, efficient G&A management, and robust operational capability—key differentiators within the AIM-listed E&P sector, where many peers face weak liquidity, high costs, and limited revenue. With approximately £250m in tax losses, improving fiscal clarity, and a solid order book of long-life producing assets, Star Energy sees significant opportunities for both onshore and offshore inorganic growth. The company reiterated its focus on maintaining EBITDA discipline, protecting margins, and optimising its portfolio through selective asset sales and strategic reinvestment. While geothermal remains a long-term low-cost growth platform, management will prioritise capital only when clear policy support emerges. The presentation also underscored the potential for G&A and operational synergies, enhanced value creation through scale, and improved utilisation of tax assets as industry investment decisions resume post-budget. Overall, Star Energy Group PLC positions itself for strengthened financial performance, revenue resilience and shareholder value growth, supported by strong operational execution, fiscal visibility, and a focused strategy to pursue both organic and inorganic expansion opportunities.

Naked Wines PLC (WINE:AIM) provided an investor update alongside its HY26 results, highlighting continued progress against guidance, improved profitability, and strengthening cash generation as the group executes its refined growth strategy. The company reported strong cash generation in the first half, including £10m of cash inflow and the completion of a £2m share buyback, while adjusted EBITDA more than doubled year-on-year to approximately £3.6m, reflecting disciplined reductions in acquisition spend, improved gross margins, and lower overheads. Revenue declined as expected due to a deliberate shift away from unprofitable customer acquisition, but performance remains in line with full-year guidance. Free cash flow was positive, inventories continued to reduce, and Naked reiterated its medium-term plan to generate up to £40m of net cash from inventory, alongside ongoing shareholder distributions. Operationally, the group is seeing encouraging trends in customer retention, lower customer acquisition costs, and improved acquisition breakeven metrics, supported by pricing actions, marketing efficiencies, and product and delivery innovations. The business continues to benefit from its diversified footprint across the UK, US, and Australia, and its direct-to-consumer model linking over half a million active customers with more than 300 independent winemakers. Management reaffirmed confidence in its strategy to return to sustainable growth through community-led advocacy, selective acquisition channels, and continued focus on margins, EBITDA growth, and capital returns, with peak trading progressing positively and FY26 guidance unchanged.

Sareum HoldingsPLC (AIM:SAR) delivered an investor update highlighting continued pipeline progress, strong clinical data and a clear growth strategy focused on value creation through partnering, non-dilutive funding and efficient cash management. The company emphasised the successful phase one results for SDC 1801, its lead autoimmune programme, demonstrating once daily oral dosing, strong human pharmacokinetics, high selectivity, no serious adverse events and exposure levels exceeding predicted therapeutic requirements without dose limiting side effects seen in rival dual-pathway inhibitors, supporting best in class potential and phase two readiness. Sareum confirmed manufacturing scale up, formulation optimisation, and a restart of its phase two enabling toxicology work in Q1 2026, funded from existing resources. Additional portfolio catalysts include translational data for SDC 1802 in haematological cancers with partnering under review, and materially improved economics for SRA 737 following acquisition of global rights, giving Sareum 63.3 percent of future revenues and supporting renewed licensing and clinical development discussions including an FDA open IND for AML and MDS. The company also expanded into neuroinflammation through a collaboration with Receptor AI to accelerate discovery of blood brain barrier penetrant TIC2 JAK1 inhibitors targeting multiple sclerosis and Parkinson’s disease. Management signalled a rebuilding of its leadership structure, continued investor engagement and commitment to non-dilutive funding. Shareholders approved all AGM resolutions including auditor reappointment, director re-elections and authorities to issue shares, reinforcing governance continuity. With a strengthened order book of clinical opportunities, high value indications in autoimmune disease and oncology, and advancing business development activity, Sareum positioned its pipeline for future revenue generation and EBITDA uplift as assets progress toward licensing milestones and later stage clinical studies.

Genedrive PLC delivered a strong investor update showcasing accelerating commercial traction, expanding clinical adoption and a clear growth strategy across its two rapid pharmacogenetic testing solutions. The company reported rising revenue, a growing order book and improving EBITDA trajectory as it moves from R&D investment to commercial scale-up. Its CE-marked and UK CA-marked MTRNR1 and CYP2C19 tests—both recommended by NICE—address critical unmet needs in neonatology, neurology and cardiology by enabling rapid, near-patient genetic testing that reduces adverse drug reactions, improves prescribing accuracy and enhances patient outcomes in time-critical care settings. Genedrive highlighted significant progress across the UK NHS, including Scotland’s national phased rollout, adoption in major hyper-acute stroke centres, early use in Ireland, and strengthening distributor-led momentum in Europe and the Middle East. The company is also advancing US market entry through FDA Breakthrough Device and 510(k) pathways. Management reinforced the substantial addressable market of approximately £190m annually across initial target geographies, supported by strong margins, recurring-revenue potential and best-in-class clinical performance. Operational efficiency remains a priority, with lean headcount, disciplined cost control and reduced monthly cash burn. Positioned at the forefront of precision medicine and backed by robust national and international clinical guidance, Genedrive PLC sees FY25 as a pivotal year—laying the foundation for scalable revenue growth, margin expansion and long-term value creation for investors.

Discoverie Group PLC delivered a strong half-year investor update, reporting record profitability, resilient company performance, and a clear pathway for sustained growth into FY26. Management highlighted a 5% increase in operating profit, a 30bps improvement in operating margins to a record 14%, and a 6% rise in adjusted earnings per share, supported by easing interest rates. The Group returned to organic revenue growth in Q2, with organic orders up 8%, and three of its four divisions achieving upper mid–single-digit organic growth as momentum builds across the portfolio. Cash generation remained exceptional, with free cash flow conversion above 100%, reinforcing discoverie’s disciplined growth strategy and long-standing track record of strong cash performance. The company continued to expand its specialist electronics platform through targeted M&A, completing two acquisitions—Kemat in the UK and Treval, a military antenna specialist in Slovenia—totalling £45.5m, with a robust pipeline of further opportunities. Management reiterated confidence in full-year financial results, noting its typical 48/52 first-half/second-half earnings weighting and no dependence on a second-half surge. Despite a challenging global backdrop, discoverie’s continued margin expansion, improving order book, and high-quality, design-led model position the Group to progress toward its medium-term 17% margin target, accelerate strategic growth, and deliver long-term value for shareholders.